The effectiveness of a Vitamin K2 analog on the recurrence of HCC after curative therapy
Not Applicable
- Conditions
- patients with HCC after curative treatment
- Registration Number
- JPRN-C000000431
- Lead Sponsor
- ational Hospital Organization Iwakuni Clinical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
(a)A planned case of postoperative interferon therapy after curative treatment of HCC (b) other malignancies (c)Vitamin K allergy (d)receiving warfarin or aspirin (e)ruptured HCC (d)Operation-related death (e)HCC reccurence detected via CT within 3 or 4 weeks (f)judged to be inadequate case of this clinical test for other reasons by doctors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method cumulative tumor recurrence rate
- Secondary Outcome Measures
Name Time Method survival